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ABSTRACT
Objective: This study proposed to study the therapeutic dosage ranges and to determine the prevalence of and the risk factors for the adverse effects 
of Thai tacrolimus-based therapy kidney transplant patients.
Methods: The fifty-nine kidney transplant patients who had kidney transplantation between January 2016 and May 2018 and were non-diabetic, 
non-hypertension, and normal kidney parameters before kidney transplantation were enrolled and followed up for 6 months. Data on graft rejection 
episodes and three significant adverse effects of tacrolimus, nephrotoxicity, hypertension (HTN), and post-transplant diabetes mellitus (PTDM) at 
each time point were recorded and analyzed.
Results: The range and mean (±standard deviation) of tacrolimus troughs level for the 204 points were 3.9–10.2 ng/ml and 6.4±1.8 ng/ml, respectively. 
About 73% of patients had HTN, 61% were on antihypertensive drugs, and 32% had PTDM. Seven patients (12%) proved to have allograft rejection 
by kidney biopsy. Only four patients did not have any three adverse effects. Similarly, laboratory parameters (SCr, BUN, and blood pressure) were 
identical during each period. All patients received prednisolone and mycophenolate mofetil as part of the comedication immunosuppressive regimen.
Conclusion: There was no significant difference between tacrolimus chronic adverse effects and therapeutic tacrolimus trough concentrations in Thai 
kidney transplant patients. Further investigations concerning pharmacokinetics and pharmacodynamics will be needed to improve the efficacy and 
safety of tacrolimus.
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INTRODUCTION
Kidney transplantation is the most frequently performed solid 
transplantation in the world. It is the best treatment of end-stage renal 
disease because it enhances survival rate, decreases complications, 
and improves the quality of life of transplant recipients. After 
transplantation, the best goal of the immunosuppressive treatment is 
to prevent graft rejection with minimal adverse effects [1].
Tacrolimus is an essential immunosuppressive agent in the calcineurin 
inhibitors, which inhibits T cells activation and reduces immune response 
to prevent graft rejection in kidney transplant patients [2]. It is widely 
used in kidney transplantation in many countries because the current 
1-year survival rate reaches more than 95% [3]. Tacrolimus has a narrow 
therapeutic window; therefore, therapeutic drug monitoring is required. 
Tacrolimus trough concentration is the standard marker of drug exposure 
and is ideal for monitoring post-transplantation clinical outcomes, especially 
allograft rejection. It is recommended at 10–15 ng/ml during the first 
3 months (induction phase), followed by 5–10 ng/ml in the maintenance 
phase. Significant toxicity is seen with trough levels of 15 ng/ml [4]. 
At Srinagarind Hospital, Thailand, the dose ranges with trough levels 
tacrolimus is 5–8 ng/ml (induction phase) and 3–5 ng/ml (maintenance 
phase), which are lower than the general information [5].
Other immunosuppressive agents that most prescribed in the kidney 
transplantation regimen are mycophenolate mofetil (MMF) and 
steroids. The frequency and type of immunosuppressive adverse effects 
are dependent on the drug regimen. Common significant adverse effects 
of tacrolimus include nephrotoxicity, hyperglycemia, and hypertension 
(HTN), which are dose-related [2,6].
Data on tacrolimus induced adverse effects are available in the United 
States and Europe. In Thailand, kidney transplant patients mostly 
receive grafts from cadaveric donors and did not have more data to 
correlate the adverse effects of tacrolimus with their dosages. The 
objectives of this study were to propose the therapeutic dosage ranges 
of tacrolimus and to estimate the prevalence of three adverse effects 
(nephrotoxicity, HTN, and post-transplant diabetes mellitus [PTDM]) 
in Thai kidney transplant patients who receive tacrolimus-based 
therapy and to assess the correlation of adverse effects with the trough 
tacrolimus blood levels, as well as with the other clinical data.
METHODS
Study design and populations
The study group consisted of 59 adult Thai kidney transplant recipients 
who had a kidney transplantation between January 2016 and June 
2018. Only cadaveric (deceased) donor kidney transplant patients were 
enrolled. Kidney transplant patients who older than 18 years of age and 
were outpatients currently on tacrolimus-based therapy were included 
in the study. Exclusion criteria were pediatric patients, patients with 
pre-transplant comorbid illness with chronic kidney disease, HTN, and 
diabetes mellitus. Endpoints of the study were at the time tacrolimus 
was discontinued or the death of patients. Patient history, clinical 
examination, and laboratory examinations were recorded on inclusion 
and after 2 weeks, 1, 3, and 6 months after kidney transplantation. This 
study was approved by the Khon Kaen University Ethics Committee 
in Human Research, which Institutional Review Board Number was 
IRB00001189 (Reference No. HE581019). Written informed consent 
was obtained from all participants.
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Immunosuppressive drugs
The immunosuppressive protocol followed in this study is a triple-
drug regimen consisting of tacrolimus, MMF, and steroids. Tacrolimus 
was started within 12 h after kidney transplantation with an initial 
dose of 0.05 mg/kg twice daily. Tacrolimus trough concentrations 
were measured every visit, and the dosage of tacrolimus was 
adjusted to achieve the range 5–8 ng/ml (induction phase) and 
3–5 ng/ml (maintenance phase). This assay was done when there was 
evidence of graft rejection. Tacrolimus trough level was detected by 
chemiluminescent microparticle immunoassay (Architect tacrolimus 
reagent kit, Abbott ARCHITECT System [i1000SR] and Abbott 
Laboratories Ltd [IL, USA]) [7].
Data collection
Data were collected between January 2016 and November 2017 and 
followed up for 6 months. Fifty-nine patients were followed up until 
May 2018. The data included daily dose of tacrolimus, tacrolimus 
trough concentrations, details of biopsy-proven graft rejection, and 
three significant adverse effects: Nephrotoxicity, HTN, and PTDM. 
Follow-up for tacrolimus-associated adverse effects after discharge was 
done at the following intervals: Twice a week for the 1st month and then 
at 3-month intervals for 6 months.
Evaluation
Tacrolimus adverse effects were recorded and analyzed at routine 
visits at 2 weeks–6 months. Clinical laboratory data were recorded and 
analyzed.
Adverse effects criteria
Patients who had serum creatinine (SCr) >1.5 mg/dl (normal range, 0.6–
1.2 mg/dl) were considered as nephrotoxicity. Persistence of elevated 
creatinine levels for more than three visits was taken as progression to 
chronic kidney disease. Biopsy-proven acute rejection was diagnosed if 
the patient increased SCr and had confirmation by kidney biopsy.
If a patient was on antihypertensive medications or had either sitting 
systolic blood pressure (BP) ≥130 mmHg, a diastolic BP ≥80 mmHg, or 
both was considered hypertensive.
PTDM was defined as when the fasting blood glucose concentration 
(FBS) was higher than 126 mg/dl or if insulin, hypoglycemic agents, 
or both were required. Steroid-induced glucose intolerance was not 
considered as PTDM. All patients were tested for fasting plasma glucose, 
HbA1C, or the presence of diabetes mellitus history for excluding 
diabetes mellitus before transplantation.
Statistical analysis
The abnormal clinical parameters and mean biochemical values were 
presented as percent means with standard deviations. All the adverse 
effects were compared between periods of follow-up. All statistical 
analyses were carried out by STATA statistical software package version 
14.1 (StataCorp LP, College Station, Texas).
RESULTS
This study was carried out to determine the prevalence of adverse 
effects of tacrolimus in Thai kidney transplant patients. Over 17 months 
(January 2016 to May 2018), a total of 59 consecutive kidney transplant 
patients visited nephrology clinics at Srinagarind Hospital for 6 months 
were included in this study. Demographic and clinical data are shown in 
Table 1. Men were recruited more than women (men 63%). All patients 
were Thais and were relatively middle age (45.6±9.6 years).
All patients received a graft from deceased donors. It should be noted 
that in one-third of patients, the primary diagnosis was unknown.
Mean tacrolimus trough blood levels during 6 months were 6.4±1.8 ng/ml 
(Fig. 1). Only 65% of patients had tacrolimus concentrations within 
the target range of 5–8 ng/ml, and 35% had a level above 8 ng/ml. 
All patients were treated with tacrolimus, prednisolone, and MMF. 
Concomitant medications included mostly antihypertensive, lipid-
lowering, hypoglycemic, antiplatelet, and anti-ulcer drugs.
Table 1 shows that seven patients had episodes of biopsy-proven 
acute rejection (12%). The rejection treatment regimens depended 
on individual patients. About 73% of renal transplantation patients 
had HTN, but only 61% had controlled BP by hypertensive agents. 
No patient had diabetes mellitus before transplantation, but PTDM 
developed in 32% of cases. One-third of patients had their FBS 
uncontrolled (>126 mg/dl).
When categorized patients into three trough levels (levels under range, 
levels in therapeutic range, and levels over range), the three significant 
chronic adverse effects (nephropathy, HTN, and PTDM) were not 
related. There was no significant difference between tacrolimus trough 
levels and chronic adverse effects, except patients with levels in the 
therapeutic range and levels over range had lower FBS <126 mg/dl, 
p<0.05 (Fig. 2).
The significant association between PTDM and the patient’s age was 
found by complementary log-log link models (p<0.001) (Table 2).
DISCUSSION
There have been few reports of long-term (6 months and longer) 
adverse effects of tacrolimus-based immunosuppression therapy in 
kidney transplant patients [8,9]. Ethnic disparity has been shown for 
clinical outcomes after organ transplantation [10]. Furthermore, few 
Table 1: Demographic and clinical characteristics of the patients 
at 6 months (n=59)
Characteristic Mean±SD/ 
n (%)
Age in years 45.6±9.6
Gender (F/M) 22/37  
(37.29/62.71)
Tacrolimus trough blood concentration (ng/ml) 6.4±1.8
Kidney function
Serum creatinine (SCr), mg/dl
• Number of patients with SCr >1.5 mg/dl
• Number of patients with SCr >2.0 mg/dl








Hypertensive patients with BP 130/80 mmHg






Fasting blood sugar (FBS) (mg/dl)
Patients with PTDM (FBS >126 mg/dl)
113.8±19.5
19 (32.20)
Fig. 1: Tacrolimus trough blood levels during the 6 months
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studies were conducted to evaluate risk factors for only some, for 
example, PTDM, alopecia, malignancies, hearing impairment, and gum 
hypertrophy [11-15], but not the three significant adverse effects of 
tacrolimus-based immunosuppressant. This study is the first report 
that evaluates the prevalence of adverse effects of tacrolimus in 
Thai tacrolimus-based therapy kidney transplant patients, in which 
tacrolimus trough levels were lower than in other western countries.
In this study, the average tacrolimus dose was 0.05 mg/kg, which 
is lower than that in the earlier studies among kidney transplant 
recipients (0.1–0.15 mg/kg) [16]. The average tacrolimus trough 
concentration was 6.4±1.8 ng/ml, very similar to that in other studies. 
Despite using lower than usual tacrolimus doses, only 65% of patients 
were maintained in the target tacrolimus range of 5–8 ng/ml compared 
to 80% in a multicenter study [17], and 35% of patients had a tacrolimus 
level exceeding 8 ng/ml, which may cause tacrolimus adverse effects. 
Such an aggressive immunosuppressive regimen may have accounted 
for the low frequency of acute rejection episodes being very similar to 
that published for living related HLA identical donors. Unfortunately, it 
could have resulted in a higher incidence of adverse effects.
The mean SCr level was 1.6±0.5 mg/dl, similar to a 3-year study in 
kidney transplant patients [17]. Tacrolimus trough concentrations 
in this study were between 3.9 and 10.2 ng/ml and were associated 
with the least overall toxicity and graft rejection. Seven patients (12%) 
proved to have graft rejection by kidney biopsy, which was lower than 
other studies around the world (15–30%) [8]. Some studies showed 
that tacrolimus trough levels were directly related to acute graft 
rejection events [18-20]. On the other hand, this study demonstrated 
no association between tacrolimus levels and acute graft rejection.
Cardiovascular morbidity and mortality among kidney transplant 
patients are substantially higher than in the general population, and 
cardiovascular disorders are responsible for about one-third of all 
deaths with a functioning graft [21]. Hyperlipidemic, diabetogenic, and 
hypertensive effects of calcineurin inhibitors such as cyclosporine and 
tacrolimus increase the risk of significant atherosclerotic cardiovascular 
disease outcomes and are believed to be risk factors for chronic graft 
nephropathy in kidney transplant patients [22].
In this study, the majority of Thai kidney transplant patients (73%) had 
HTN, which was much more prevalent than in other studies in organ 
transplantation patients (10–68%) [4,9,23,24]. It should be noted that 
the incidence of HTN per 100,000 population was 1,146.70 in 2015. It 
was lower than the United States population (30% in males and 27% 
in females) [25]. Despite a high prevalence of HTN among kidney 
transplantation patients in Thai, the mean number of antihypertensive 
medications was lower than in a study where patients were converted 
from cyclosporine to tacrolimus [22].
PTDM is a common complication of kidney transplant patients. It is 
associated with an increased incidence of infectious and cardiovascular 
complications, impaired long-term graft function, and reduced survival 
rate [26]. Although most of the patients develop PTDM in the first 3 
months after transplantation, its incidence increases with follow-
up [27]. PTDM was identified in 32% of our patients, close to results 
obtained in cadaveric kidney transplant patients in Japan (29%) [11].
The estimated national prevalence of diabetes in Thai adults was 
less than in our study in kidney transplant patients (7.5% vs. 33%, 
p<0.05) [28]. PTDM patients in our study were 32%, which is close 
to results in the 3-year study in cardiac transplantation patients in 
Germany (29%) [29]. Mean fasting blood sugar in this study was lower 
than in cardiac transplantation patients (108 mg/dl vs. 114 mg/dl) [29]. 
However, only about half of diabetic patients in our study achieved 
glycemic control.
CONCLUSION
This study demonstrated a significant prevalence of cardiovascular and 
metabolic adverse effects in long-term kidney transplant recipients 
from cadaveric donors. These adverse effects may be explained in part 
by elevating tacrolimus blood concentrations despite low tacrolimus 
doses. It would be useful to assess more carefully the tacrolimus 
dose-concentration relationship among Thai kidney transplant 
patients. Further investigations concerning pharmacokinetics and 
pharmacodynamics will be needed to evaluate the efficacy and safety 
of tacrolimus. In addition, identifying patients at high risk for the 
development of tacrolimus induced three significant adverse effects 
will help clinicians to select the proper immunosuppressant dose to 
avoid these three adverse effects.
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